Third, there are no controlled trials directly testing this combination in humans
Ultrasound-based assessments and individualized patient management will likely shape future guidelines
In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) clinical trial and the Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) clinical trial, treatment with liraglutide or semaglutide compared with placebo resulted in fewer patients experiencing a composite cardiovascular outcome and decreased risk of CKD development and progressionbenefits mainly driven by the reduction in new-onset macroalbuminuria (2, 3, 5)
Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-Nvoa F et al (2023) Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
Frequently Asked Questions How often do gastrointestinal side effects show up in tirzepatide trials
